Baudax Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Capital Structure - Additional Information (Details)

Capital Structure - Additional Information (Details) $ / shares in Units, $ in Thousands								9 Months Ended
	Oct. 19, 2020 Holder $ / shares shares	May 29, 2020 $ / shares shares	Mar. 26, 2020 $ / shares shares	Feb. 13, 2020 USD ($) $ / shares	Jan. 01, 2020 shares	Nov. 21, 2019 shares	Nov. 15, 2019 shares	Sep. 30, 2020 USD ($) $ / shares shares	Nov. 05, 2020 shares	Dec. 31, 2019 $ / shares shares
Schedule Of Capitalization Equity [Line Items]
Common stock, shares authorized to issue								100,000,000		100,000,000
Common stock, par value \| $ / shares								$ 0.01		$ 0.01
Proceeds from public offering, net of transaction costs \| $								$ 23,085
Common stock in public offering			7,692,308
Warrant to purchase of common stock								527,100
Proceeds from issuance of common stock underwriting discounts and commissions and offering expenses \| $								$ 23,085
Preferred stock, shares authorized								10,000,000		10,000,000
Preferred stock, par value \| $ / shares								$ 0.01		$ 0.01
Preferred stock, shares issued								0		0
Preferred stock, shares outstanding								0		0
Common stock, shares issued								18,374,604		9,350,709
Series A Warrants \| Subsequent Event
Schedule Of Capitalization Equity [Line Items]
Common stock, shares issued									6,677,447
Warrants outstanding									64,738
Series B Warrants \| Subsequent Event
Schedule Of Capitalization Equity [Line Items]
Common stock, shares issued									6,677,447
Warrants outstanding									1,903,969
MAM Eagle Lender, LLC
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock		527,100
Common stock exercisable price per share \| $ / shares		$ 4.59
Series A Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock			7,692,308					7,692,308
Common stock exercisable price per share \| $ / shares			$ 4.59
Series B Warrants
Schedule Of Capitalization Equity [Line Items]
Common stock in public offering								804,616
Warrant to purchase of common stock			7,692,308					6,887,692
Common stock exercisable price per share \| $ / shares			$ 3.25
Proceeds from issuance of warrants \| $								$ 2,458
The Agreement
Schedule Of Capitalization Equity [Line Items]
Issuance of common stock upon separation								441,967
Common stock, par value \| $ / shares				$ 0.01
Proceeds from sales agreement \| $								$ 3,612
Proceeds from public offering, net of transaction costs \| $				$ 25,000
Paid sales commission								3.00%
Exchange Agreement \| Subsequent Event
Schedule Of Capitalization Equity [Line Items]
Agreement expiration date	Oct. 21, 2020
Common stock, shares issued	1,186,774
Exchange Agreement \| Series A Warrants \| Subsequent Event
Schedule Of Capitalization Equity [Line Items]
Common stock, par value \| $ / shares	$ 0.01
Warrant to purchase of common stock	8,646,154
Warrants issued to purchase shares of common stock	0.2
Number of holders exchange warrants \| Holder	0
Warrants expiration date	Apr. 26, 2021
Exchange Agreement \| Series B Warrants \| Subsequent Event
Schedule Of Capitalization Equity [Line Items]
Common stock, par value \| $ / shares	$ 0.01
Warrant to purchase of common stock	8,646,154
Warrants issued to purchase shares of common stock	0.2
Number of holders exchange warrants \| Holder	0
Warrants expiration date	Apr. 26, 2021
Recro
Schedule Of Capitalization Equity [Line Items]
Right to receive common stock						1
Number of shares held for distribution of new shares							2.5
Issuance of common stock upon separation					45,874	9,396,583